Ype P. de Jong, M.D., Ph.D.

Gastroenterology
Ype de Jong

Dr Ype de Jong is an Assistant Professor of Medicine at the Sanford I. Weill Medical College of Cornell University andan Attending Physician, New York-Presbyterian Hospital Cornell campus. He joined the faculty after completing his Internal Medicine and Gastroenterology training at Mount Sinai Hospital, New York. In his patient practice Dr. de Jong's interests include viral hepatitis, Primary Biliary Cirrhosis, and Non-Alcoholic Fatty Liver Disease as well as liver disease associated with Inflammatory Bowel Disease. In addition he is trained in general Gastroenterology, including endoscopy and colon cancer screening. His research interests are geared to better understanding how hepatitis viruses can evade the immune system and are able to chronically persist in a subset of those infected. To this end he is working on developing new models for hepatitis C virus infection in the basic science arm of the Center for the Study of Hepatitis C at The Rockefeller University.

Ype de Jong studied medicine at the University of Amsterdam Medical School. After completing his master's in Amsterdam he conducted research into the immunopathogenesis of Crohn’s disease at the Beth Israel Deaconess Medical Center in Boston, with which he obtained his PhD. He subsequently completed his Internal Medicine internship and residency at the Mount Sinai Hospital in New York, followed by a fellowhip in Gastroenterology at the same institution. He currently is an Assistant Professor of Medicine at Weill-Cornell Medical College. Dr de Jong is an intricate part of the Center for the Study of Hepatitis C, both as a physician at New York-Presbyterian Hospital and as a Visiting Clinical Fellow at The Rockefeller University.

 

 

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup
  • Health Plus - Amerigroup [CHP]
  • Health Republic
  • Medicaid
  • Medicare
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Oxford Health Plans [Liberty]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • VNSNY CHOICE Medicare [HMO]

Publications

1. Simpson SJ, Shah S, Comiskey M, de Jong YP, Wang B, Mizoguchi E, Bhan AK, Terhorst C. T cellmediated

pathology in two models of experimental colitis depends predominantly on the interleukin

12/Stat-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 1998;

187(8): 1225-34.

 

2. Levelt CN, de Jong YP, Mizoguchi E, O'Farrelly C, Bhan AK, Tonegawa S, Terhorst C, Simpson SJ.

High- and low-affinity single-peptide/MHC ligands have distinct effects on the development of mucosal

CD8αα and CD8αβ T lymphocytes. Proc Natl Acad Sci USA 1999; 96(10): 5628-33.

 

3. de Jong YP, M Comiskey, SL Kalled, E Mizoguchi, AK Bhan, Terhorst C. Chronic experimental colitis is

dependent on the CD40-CD154 pathway and can be attenuated by anti-CD154 administration.

Gastroenterology 2000 Sep; 119(3):715-23.

 

4. de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, ten Hove T, Al Sahli

M, Mizoguchi E, Metz CN, Michetti P, van Deventer SJ, David JR, Bhan AK, Terhorst C. Chronic colitis

is dependent on the cytokine MIF. Nat Immunol 2001 Nov; 2(11): 1061-6.

 

5. de Jong YP, Rietdijk ST, Abadia-Molina AC, Faubion WA, Clarke K, Delaney T, Mizoguchi E, Guiterrez-

Ramos JC, Bhan AK, Coyle AJ, Terhorst C. Blocking ICOS in the absence of CD28 impairs T helper 1

and CD25 regulatory T cells in murine colitis. Int Immunol 2004 Feb 16(2):205-213.

 

6. Faubion WA, de Jong YP, Abadia-Molina AC, Clarke K, Wang B, Mizoguchi E, Simpson SJ, Bhan AK,

Terhorst C. Colitis is associated with thymic destruction attenuating CD4 CD25 regulatory T cells in

the periphery. Gastroenterology. 2004; 126(7): 1759-70.

 

7. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a

hepatitis c virus entry factor required for infection of mouse cells. Nature, 2009;457(7231):882-6. NIHMS

102188

 

8. Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, Brezillon N, Debarry J, de Jong Y, Deng H, Di

Santo JP et al. Humanized mice for modeling human infectious disease: challenges, progress, and

outlook. Cell Host Microbe, 2009 Jul 23;6(1):5-9. Review.

 

9. de Jong BC, Antonio M, Awine T, Ogungbemi K, de Jong YP, Gagneux S, DeRiemer K, Rastogi N,

Borgdorff M, Hill PC, Adegbola RA. Use of spoligotyping and large-sequence polymorphisms to study

the population structure of the Mycobacterium tuberculosis complex in a cohort study of consecutive

smear positive tuberculosis cases in the Gambia. J Clin Micro 2009; 47(4): 994-1001. PMC2668362

 

10. de Jong YP, Rice CM, Ploss A. New horizons for studying human hepatotropic infections. J Clin Invest. 2010 Mar 1;120(3):650-3. Commentary.

Honors and Awards

Cum Laude (for PhD thesis), University of Amsterdam, 2002

Hippocrates Prize (for best medical thesis in The Netherlands), Leiden University, 2003